Journal
FEBS LETTERS
Volume 586, Issue 4, Pages 303-309Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.febslet.2011.12.036
Keywords
SM22; Hypoxia; Chemo-resistance; IGF1R beta; PI3K/Akt
Funding
- Ministry of Education, Science and Technology of the Republic of Korea
- Korean Atomic Energy Research Institute
- Korean Science and Engineering Foundation (KOSEF) [OGM2001013]
Ask authors/readers for more resources
Chemo- or radiation-resistance in tumors caused by hypoxia often undermines efficacy of cancer therapy. Thus, therapies that overcome cellular resistance during hypoxia are necessary. SM22 alpha is an actin-binding protein found in smooth muscle, fibroblasts, and some epithelium. We demonstrate that SM22 alpha is induced in A549 non-small cell lung carcinoma cells by hypoxia and its overexpression increased chemo- and radiation-resistance. Hypoxia-mediated induction of SM22 alpha expression is hypoxia-inducible factor-independent. Moreover, SM22 alpha overexpression enhances tumor cell growth and activates the IGF1R/PI3K/Akt pathway via direct interaction with IGF1R beta. Our results suggest SM22 alpha as a novel regulator of hypoxic survival pathway of A549 NSCLC cells. Structured summary of protein interactions: IGFR1 Beta physically interacts with SM22 alpha by anti bait coimmunoprecipitation (View Interaction: 1, 2) (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available